PB1 Inhibitors
PB1 inhibitors represent a diverse set of chemicals capable of directly or indirectly modulating the function of PB1, a protein involved in various cellular processes. Dasatinib, a tyrosine kinase inhibitor, directly inhibits PB1 by disrupting its phosphorylation and activation, impacting downstream signaling events. Sorafenib, a multi-kinase inhibitor, indirectly inhibits PB1 by targeting Raf/MEK/ERK and VEGFR signaling pathways, influencing cellular processes regulated by PB1. U0126, a selective MEK1/2 inhibitor, disrupts the MAPK pathway, modulating PB1 activity and downstream events. Rapamycin, an mTOR inhibitor, indirectly inhibits PB1 by interfering with the mTOR signaling pathway. SP600125, a JNK inhibitor, indirectly inhibits PB1 by disrupting the JNK signaling pathway, influencing cellular processes associated with PB1 function.
Gefitinib, an EGFR inhibitor, indirectly inhibits PB1 by interfering with EGFR signaling. SB203580, a p38 MAPK inhibitor, indirectly inhibits PB1 by disrupting the p38 MAPK signaling pathway. LY294002, a PI3K inhibitor, indirectly inhibits PB1 by interfering with the PI3K/Akt signaling pathway. AG490, a JAK2 inhibitor, indirectly inhibits PB1 by disrupting the JAK/STAT signaling pathway. 17-AAG, an Hsp90 inhibitor, indirectly inhibits PB1 by interfering with Hsp90 chaperone function, impacting the stability of PB1. Nilotinib, a tyrosine kinase inhibitor, directly inhibits PB1 by disrupting its phosphorylation and activation. Selumetinib, a selective MEK1/2 inhibitor, directly inhibits PB1 by disrupting the MAPK pathway. The diverse mechanisms of these inhibitors provide researchers with valuable tools to dissect PB1's role in cellular processes, offering insights for further exploration in physiological and pathological contexts.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that directly inhibits PB1 by disrupting its phosphorylation and activation. As a potent inhibitor of multiple tyrosine kinases, including those involved in PB1 signaling pathways, Dasatinib interferes with the downstream events mediated by PB1, impacting cellular processes associated with its function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly inhibits PB1 by targeting various signaling pathways. By disrupting the Raf/MEK/ERK and VEGFR signaling pathways, Sorafenib influences the cellular processes regulated by PB1. Its impact on these pathways can lead to modulation of PB1 activity and downstream events, providing a potential avenue for inhibiting PB1-mediated functions in cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits PB1 by interfering with the mTOR signaling pathway. By inhibiting mTOR, Rapamycin disrupts the downstream events regulated by PB1, impacting cellular processes associated with its function. The inhibition of mTOR by Rapamycin provides a potential avenue for indirectly targeting PB1-mediated functions in cellular contexts. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that indirectly inhibits PB1 by disrupting the JNK signaling pathway. Through the inhibition of JNK, SP600125 influences the downstream events regulated by PB1, leading to the modulation of PB1 activity and the cellular processes associated with its function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor that indirectly inhibits PB1 by interfering with EGFR signaling. By inhibiting EGFR, Gefitinib disrupts the downstream events regulated by PB1, impacting cellular processes associated with its function. The inhibition of EGFR by Gefitinib provides a potential avenue for indirectly targeting PB1-mediated functions in cellular contexts. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that indirectly inhibits PB1 by disrupting the p38 MAPK signaling pathway. Through the inhibition of p38 MAPK, SB203580 influences the downstream events regulated by PB1, leading to the modulation of PB1 activity and the cellular processes associated with its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that indirectly inhibits PB1 by interfering with the PI3K/Akt signaling pathway. By inhibiting PI3K, LY294002 disrupts the downstream events regulated by PB1, impacting cellular processes associated with its function. The inhibition of PI3K by LY294002 provides a potential avenue for indirectly targeting PB1-mediated functions in cellular contexts. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 is a JAK2 inhibitor that indirectly inhibits PB1 by disrupting the JAK/STAT signaling pathway. Through the inhibition of JAK2, AG490 influences the downstream events regulated by PB1, leading to the modulation of PB1 activity and the cellular processes associated with its function. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG is an Hsp90 inhibitor that indirectly inhibits PB1 by interfering with the Hsp90 chaperone function. By inhibiting Hsp90, 17-AAG disrupts the proper folding and stability of PB1, leading to the modulation of PB1 activity and the cellular processes associated with its function. The inhibition of Hsp90 by 17-AAG provides a potential avenue for indirectly targeting PB1-mediated functions in cellular contexts. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a tyrosine kinase inhibitor that directly inhibits PB1 by disrupting its phosphorylation and activation. As a specific inhibitor of tyrosine kinases involved in PB1 signaling pathways, Nilotinib interferes with the downstream events mediated by PB1, impacting cellular processes associated with its function. | ||||||